Smith & Nephew SNATS ROA 2006-2018 | SNN

Current and historical return on assets (ROA) values for Smith & Nephew SNATS (SNN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Smith & Nephew SNATS ROA for the three months ending June 30, 2018 was 0.00%.
Smith & Nephew SNATS ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-06-30 $0.00B $7.71B 0.00%
2017-12-31 $0.00B $7.87B 0.00%
2017-06-30 $0.00B $7.44B 0.00%
2016-12-31 $0.16B $7.34B 2.20%
2015-12-31 $0.26B $7.17B 3.57%
2015-06-30 $0.35B $7.22B 4.69%
2014-12-31 $0.50B $7.31B 7.00%
2014-09-30 $0.50B $7.65B 7.41%
2014-06-30 $0.52B $7.74B 8.35%
2014-03-31 $0.56B $5.94B 9.89%
2013-12-31 $0.56B $5.82B 9.97%
2013-09-30 $0.54B $5.57B 9.69%
2013-06-30 $0.55B $5.45B 10.17%
2013-03-31 $0.71B $5.47B 13.60%
2012-12-31 $0.73B $5.64B 14.34%
2012-09-30 $0.73B $5.00B 14.96%
2012-06-30 $0.73B $4.81B 15.07%
2012-03-31 $0.59B $4.88B 12.13%
2011-12-31 $0.58B $4.75B 12.08%
2011-09-30 $0.62B $4.82B 12.96%
2011-06-30 $0.63B $4.91B 13.01%
2011-03-31 $0.61B $4.79B 12.90%
2010-12-31 $0.62B $4.73B 13.13%
2010-09-30 $0.56B $4.88B 12.09%
2010-06-30 $0.55B $4.58B 12.06%
2010-03-31 $0.53B $4.54B 11.69%
2009-12-31 $0.47B $4.57B 10.48%
2009-09-30 $0.46B $4.63B 10.22%
2009-06-30 $0.41B $4.52B 9.07%
2009-03-31 $0.39B $4.31B 8.64%
2008-12-31 $0.38B $4.51B 8.15%
2008-09-30 $0.36B $4.53B 7.87%
2008-06-30 $0.30B $4.71B 6.63%
2008-03-31 $0.31B $4.67B 6.99%
2007-12-31 $0.32B $4.45B 7.81%
2007-09-30 $0.36B $4.28B 9.49%
2007-06-30 $0.44B $4.23B 12.53%
2007-03-31 $0.42B $3.22B 13.24%
2006-12-31 $0.75B $3.23B 23.69%
2006-09-30 $0.70B $3.20B 22.12%
2006-06-30 $0.67B $3.16B 21.52%
2006-03-31 $0.67B $3.10B 21.59%
2005-12-31 $0.34B $3.19B 11.10%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.007B $4.765B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $124.342B 19.06
Abbott Laboratories (ABT) United States $122.048B 24.73
Stryker (SYK) United States $62.796B 23.67
Boston Scientific (BSX) United States $50.730B 25.64
Baxter (BAX) United States $33.541B 21.66
Zimmer Biomet Holdings (ZBH) United States $23.031B 14.94
ResMed (RMD) United States $14.492B 27.64
Canopy Growth (CGC) Canada $8.934B 0.00
Perrigo (PRGO) Ireland $8.884B 13.48
Bio-Rad Laboratories (BIO) United States $8.054B 51.50
Aurora Cannabis (ACB) Canada $6.462B 35.26
Hill-Rom Holdings (HRC) United States $6.201B 19.66
Haemonetics (HAE) United States $5.495B 48.33
Insulet (PODD) United States $4.770B 0.00
ICU Medical (ICUI) United States $4.529B 25.23
Hutchison China MediTech (HCM) China $4.274B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.987B 0.00
Agios Pharmaceuticals (AGIO) United States $3.869B 0.00
Neogen (NEOG) United States $3.219B 48.74
National Vision Holdings (EYE) United States $3.101B 61.33
NuVasive (NUVA) United States $2.972B 27.65
Aphria (APHA) $2.572B 0.00
Quidel (QDEL) United States $2.478B 32.30
NxStage Medical (NXTM) United States $1.924B 0.00
Phibro Animal Health (PAHC) United States $1.476B 20.89
AtriCure (ATRC) United States $1.174B 0.00
Cardiovascular Systems (CSII) United States $1.015B 1462.50
VAREX IMAGING (VREX) United States $0.992B 19.93
Meridian Bioscience (VIVO) United States $0.827B 26.35
PetIQ (PETQ) United States $0.803B 22.83
OraSure Technologies (OSUR) United States $0.793B 44.65
Surmodics (SRDX) United States $0.776B 118.55
Eagle Pharmaceuticals (EGRX) United States $0.755B 24.22
Cerus (CERS) United States $0.719B 0.00
MacroGenics (MGNX) United States $0.710B 0.00
Omeros (OMER) United States $0.623B 0.00
Lantheus Holdings (LNTH) United States $0.590B 18.27
Owens & Minor (OMI) United States $0.558B 6.31
Insys Therapeutics (INSY) United States $0.542B 0.00
LeMaitre Vascular (LMAT) United States $0.518B 25.45
NanoString Technologies (NSTG) United States $0.481B 0.00
TG Therapeutics (TGTX) United States $0.438B 0.00
Evolus (EOLS) United States $0.399B 0.00
Quanterix (QTRX) United States $0.359B 0.00
Utah Medical Products (UTMD) United States $0.327B 21.12
Cytosorbents (CTSO) United States $0.302B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.255B 0.00
Surface Oncology (SURF) United States $0.226B 0.00
Rockwell Medical (RMTI) United States $0.211B 0.00
BioLife Solutions (BLFS) United States $0.206B 278.75
Bovie Medical (BVX) United States $0.201B 0.00
Chimerix (CMRX) United States $0.161B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.148B 0.00
Fonar (FONR) United States $0.139B 6.96
Chembio Diagnostics (CEMI) United States $0.104B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.081B 0.00
United-Guardian (UG) United States $0.079B 16.63
Female Health (VERU) United States $0.079B 0.00
Trinity Biotech (TRIB) Ireland $0.077B 24.40
Oramed Pharmaceuticals (ORMP) Israel $0.070B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
CAS Medical Systems (CASM) United States $0.056B 0.00
Neurotrope (NTRP) United States $0.050B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
Capricor Therapeutics (CAPR) United States $0.028B 0.00
Myomo (MYO) United States $0.025B 0.00
Valeritas Holdings (VLRX) United States $0.021B 0.00
Senestech (SNES) United States $0.019B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.019B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.000B 0.00